# Pamishield signs 6-year supply contract with UCB for mPEG-20k

Pamishield (파미셀) signed a 6-year contract with Belgian pharmaceutical company UCB to supply mPEG-20k, a raw material for the autoimmune disease drug Cimzia. The contract is effective from January 23, 2017, with automatic one-year renewals thereafter.

- Type: Contract
- Announced: 2017-01-23
- Where: South Korea
- Status: announced
- Products: mPEG-20k (Methoxy-Polyethylene glycol-20k)
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Pamishield](https://endata.com/companies/21618.md) (supplier)
- [UCB](https://endata.com/companies/21619.md) (customer)

## Sources

- [medicaltimes.com](https://www.medicaltimes.com/Mobile/News/NewsView.html?ID=1109621), 2017-01-23: "파미셀(대표 김현수·김성래)은 벨기에 다국적 제약사 UCB사와 mPEG-20k(Methoxy-Polyethylene glycol-20k) 공급계약을 맺었다고 밝혔다."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.